New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 26, 2014
14:35 EDTAUXLAuxilium deal unappealing, says Brean Capital
Brean Capital believes that Auxilium's (AUXL) merger with Canada's QLT is unlikely to benefit Auxilium financially. Auxilium is unlikely to benefit from tax breaks fro mthe deal, given the likelihood that it will continue to report losses, according to Brean. Moreover, the deal suggests that no company was interested in buying Auxilium, according to Brean ,which keeps a $14 price target and Sell rating on the shares.
News For AUXL From The Last 14 Days
Check below for free stories on AUXL the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 21, 2014
09:07 EDTAUXLOn The Fly: Pre-market Movers
Subscribe for More Information
07:32 EDTAUXLAuxilium announces positive data from Phase 2a study of CCH with cellulite
Subscribe for More Information
August 18, 2014
11:41 EDTAUXLCubist rises after report sparks takeover interest speculation
Subscribe for More Information
August 11, 2014
11:04 EDTAUXLActive equity options trading on open
Subscribe for More Information
06:09 EDTAUXLAuxilium appoints Andrew Saik as CFO
Subscribe for More Information
August 8, 2014
08:34 EDTAUXLBioSpecifics announces initiation of Phase 2 clinical study of CCH
BioSpecifics (BSTC) announced that it has injected the first patient in its placebo-controlled Phase 2 clinical trial of CCH for the treatment of lipoma. The company expects to complete patient enrollment in this trial during the first quarter of 2015. The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study to assess the safety and efficacy of CCH for the treatment of lipoma. The primary endpoint of the Phase 2 clinical trial is the reduction in the measureable surface area of the target lipomas, as determined by caliper, at six months post injection. The secondary efficacy endpoints include responders at six months post injection who show a ≥50% decrease in lipoma surface area relative to baseline between CCH and placebo, the change in the length of the target lipoma, the relative change in lipoma surface area as measured by caliper at one month and three months, and the relative change in lipoma volume as measured by MRI. The study will also gather qualitative lipoma characteristics and an assessment of patient satisfaction through a questionnaire administered to each subject prior to injection and at each follow-up visit. BioSpecifics' strategic partner Auxilium (AUXL) has the option to license development and marketing rights to this indication based on a full analysis of the data from this Phase 2 clinical trial, which would transfer responsibility for the future development costs to Auxilium and trigger an opt-in payment and potential future milestone and royalty payments from Auxilium to BioSpecifics.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use